Evidence map›Paper›PMID 29874247›Full record

ArticlePloS one2018

"I found that I was well and strong": Women's motivations for remaining on ART under Option B+ in Malawi.

Nozgechi Phiri, Andreas D Haas, Malango T Msukwa, Lyson Tenthani, Olivia Keiser, Kali Tal

Abstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nozgechi PhiriInstitute of Global Health, University of Geneva, Geneva, Switzerland.
Andreas D HaasInstitute for Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Malango T MsukwaInstitute of Global Health, University of Geneva, Geneva, Switzerland.
Lyson TenthaniInstitute for Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Olivia KeiserInstitute of Global Health, University of Geneva, Geneva, Switzerland.
Kali TalInstitute of Global Health, University of Geneva, Geneva, Switzerland.ORCID 0000-0003-2454-2560

Funding

Observational Antiretroviral Studies In Southern Africa (OASIS) CollaborationU01AI069924 · NIAID · UNIVERSITAT BERN · PI Cleophas Chimbetete, Mary-Ann Davies · 2006 to 2026
$55.9M
NIAID NIH HHS U01 AI069924PEPFAR
6 · The paper itself

Abstract

Most Malawian women who start ART under Option B+ are still in care three years later, a higher than average adherence rate for life-threatening chronic disease treatments, worldwide (50%). We asked 75 Malawian on ART their motivations for remaining in treatment, and what barriers they overcame. Focus groups and interviews included 75 women on ART for 6+ months, at 12 health facilities. Four main motivations for continuing ART emerged: 1) evidence that ART improved their own and their children's health; 2) strong desire to be healthy and keep their children healthy; 3) treatment was socially supported; 4) HIV/ART counselling effectively showed benefits of ART and told women what to expect. Women surmounted the following barriers: 1) stigma; 2) health care system; 3) economic; 4) side effects. Women stayed on ART because they believed it works. Future interventions should focus on emphasizing ART's effectiveness, along with other services they provide.

Indexed as

MotivationAdolescentAdultAnti-HIV AgentsChildCounselorsFemaleHIV InfectionsHumansInfectious Disease Transmission, VerticalMalawiRural PopulationUrban PopulationYoung AdultAnti-HIV Agents

Identifiers

PMID29874247
PMCPMC5991368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.